Liu and Fu are equally contributed to this study. Objective: This study was designed to investigate the value of applying sigma metrics derived from different standards for allowable total error (TEa) in evaluating the analytical quality of tumor marker assays.
| INTRODUC TI ON
Detection of tumor markers is widely conducted in medical laboratories in China. The results of detection assays for the same specimen are usually quite different in different laboratories or when tested with different detection systems.
1 Therefore, it is necessary to improve the quality control of tumor marker detection to ensure accurate and credible results.
Sigma refers to "standard deviation" in mathematical statistics
and is often used to express the defects per million (dpm) when measuring the performance of production processes. Six Sigma represents a defect rate of detection of 3.4 dpm. 2 Six Sigma theory was first applied in the field of medicine by Nevakainen et al.
3
As understanding of this theory spread, Six Sigma became an important quality management tool. Therefore, an increasing number of researchers have used Six Sigma to study quality improvement in laboratories. [4] [5] [6] The sigma metric can evaluate the measurement performance of different assay processes as the quality targets and their sigma values differ. 
| Tumor markers
The following markers were assessed: total prostate-specific antigen (tPSA), carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), carbohydrate antigen 199 (CA199), carbohydrate antigen 125 (CA125), and carbohydrate antigen 153 (CA153).
| Instruments and reagents
The tumor markers were measured by chemiluminescence using the AIA2000 automatic chemiluminescence analyzer and corresponding reagents (TOSOH Co., Ltd., Tokyo, Japan). Calibrator was the TA B L E 1 Coefficient of variation, bias, and total allowable error based on four standards for six tumor marker assays 
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| Assay performance evaluation
| Evaluation of precision
The coefficient of variation (CV) was used to represent precision.
We collected laboratory quality control data from the tumor marker program at our laboratory over 6 months from January 2017 to June 2017 and determined CV values for two concentration levels of quality control products (level 1 and level 2; Table 1 ).
| Evaluation of bias
Percentage difference was used to evaluate bias. Based on first-time data from the first tumor marker assays performed in 2017, the laboratory obtained a 5-percent difference. The absolute value of the mean percentage difference was used to evaluate the bias of our laboratory (Table 1) .
| Calculation of sigma value
Sigma values were calculated using this formula: sigma = [TEa (%) − bias (%)]/CV (%). Sigma values were determined for four different TEa standards and two concentration levels of quality control products.
| Calculation of quality goal index
The quality goal index (QGI) was calculated according to this formula: QGI = bias (%)/1.5 × CV (%). We calculated the QGI for each tumor marker at both concentrations of quality control products, noted differences in QGI corresponding to different sigma values, and determined priority measures for quality improvement. When QGI was <0.8, the CV was relatively large, suggesting that the priority should be to improve precision. When QGI was higher than 1.2, the bias was relatively large, suggesting that the priority should be to improve accuracy. A QGI between 0.8 and 1.2 suggested that both precision and accuracy should be improved.
| RE SULTS
| Distribution of sigma metrics for four total allowable error standards
Using the EQA standards of China, the distribution of sigma values for the six tumor marker assays was as follows (Table 2 ): more than 6, none; 4 to 6, 66.7% (4/6); and less than 4, 33.3% (2/6). Using the RCPA standards, all sigma values were <4. Using the "appropriate" standards, the distribution of sigma values was as follows: more than 6, 16.7% (1/6); 4 to 6, 33.3% (2/6); and less than 4, 50% (3/6). Using the German RiliBÄK standards, the distribution of sigma values was the same as for the EQA standards of China (Table 2 ).
| Quality corrective actions
Using the EQA standards of China, the QGI was calculated for tumor marker assays with sigma values <6 (ie, all tumor marker assays). The results showed that for tPSA, both precision and accuracy required improvement, whereas for the other markers, only measures to improve precision are required (Table 3 ).
| Measures of internal quality control
Using the EQA standards of China, Westgard sigma rules were used to develop individualized internal quality control measures.
The Westgard sigma rules for two levels of controls are shown in 
| D ISCUSS I ON
Our study used four different TEa standards to calculate sigma values of six tumor markers. RCPA standards are the strictest, "appropriate" standards based on biological variability are the least strict, and the EQA standards of China and German RiliBÄK standards exhibit intermediate levels of strictness. Especially for CA199 and CA 125, these two values are assumed values, the same as for CA153 (Table 1 ). Using the current EQA standards of China, the sigma values of all six tumor markers in our laboratory were <6, indicating that assay performance for these markers requires quality improvement. Using TEa derived from biological variation, Westgard et al suggested that no less than two concentrations of quality control products should be used every day for internal quality control to ensure acceptable test results. 15 Xia et al 16 also showed that sigma metric is a useful tool to evaluate assay performance and suggested that an assay with a high sigma value could use a simple internal quality control rule, whereas an assay with a low sigma value should be monitored strictly. The conclusions of our study are in agreement with the results of the above scholars, indicating that sigma metrics can play an important role in the field of quality control. has an important guiding value for evaluating the quality of tumor marker assays.
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